Director, Global Transactions and Contracts Management, Boehringer Ingelheim Pharmaceuticals, Inc., Connecticut USA
As Boehringer Ingelheim’s Director, Global Transactions and Contracts Management, Gaylene is responsible for negotiating license/collaboration deals, research agreements, and managing strategic alliance programs. Prior to joining BI, Gaylene served as the Director, Cleveland Clinic/ University of Notre Dame Global Alliance Commercialization Program – managing all life science IP, negotiating license deals and research opportunities, and spinning out startup companies.
Throughout her career, Gaylene has had a strong focus on economic development and entrepreneurship activities. As a result, she has created over a dozen startup companies, developed relationships with investor groups around the U.S., and helped grow research collaboration opportunities for university programs. Prior to the Cleveland Clinic, she worked for the University of Idaho and the University of Hawaii, as a Senior Licensing Associate.
Gaylene has won several leadership awards for her work with faculty and students, particularly with respect to her entrepreneurial accomplishments (including her own company, Waterproof Kids®).
Chair of the BIH Board of Directors and Chief Translational Research Officer of Charité – Universitätsmedizin Berlin, Germany
Professor Christopher Baum
Professor Christopher Baum was born in 1962 in Marburg. He studied philosophy for two semesters in Mainz, and medicine in Essen, Freiburg and Hamburg. He obtained his doctorate in 1991, and qualified as a professor in the field of molecular medicine in 1999 at the University of Hamburg. In 2000, he joined the Hannover Medical School (MHH) as a professor for stem cell biology, and was also an associate professor of pediatrics at the Cincinnati Children’s Hospital in the United States from 2002. In Hanover, he led the Institute of Experimental Hematology from 2006 and served as both the Ombudsperson for Good Scientific Practice and the Dean of Research. He was elected President of the MHH in 2013. At the beginning of 2019, Baum moved to the University of Lübeck as its first full-time Vice President for Medicine and a member of the Board of Directors of UKSH – Germany’s second largest university hospital after Charité. Since October 2020 Christopher Baum has been Chief Executive Officer of th Berlin Institute of Health (BIH). With the integration of the BIH into the Charité – Universitätsmedizin Berlin, Baum has become Chair of the BIH Board of Directors and Chief Translational Research Officer of Charité – Universitätsmedizin Berlin.
Managing Director at Flying Health GmbH, Berlin, Germany
Lina Behrens is a Managing Director at Flying Health, the leading ecosystem for Next Generation Healthcare. She is also Vice President of the German Startup Association and a Member of the Advisory Board „Junge Digitale Wirtschaft“ (Young Digital Economy) of the German Federal Ministry of Economics and Energy. Previously, Lina worked at the Boston Consulting Group (BCG) and at Polymath Ventures, one of the largest company builders in Latin America. Lina holds an MPA from the London School of Economics and a BA in Economics and in International Affairs from the University of St. Gallen.
Chief Innovation Officer at Boston Children’ Hospital, Boston, Massachusetts, USA
John Brownstein, PhD
Professor of Biomedical Informatics at Harvard Medical School and is the Chief Innovation Officer of Boston Children’s Hospital. He also directs the Computational Epidemiology Lab and the Innovation and Digital Health Accelerator both at Boston Children’s. He was trained as an epidemiologist at Yale University. Overall, his work aims to have translation impact on the surveillance, control and prevention of disease. He has been at the forefront of the development and application of data mining and citizen science to public health. His efforts are in use by millions each year including the CDC, WHO, DHS, DOD, HHS, and EU, and has been recognized by the National Library of Congress and the Smithsonian. In addition to research achievements, this translational impact comes from playing an advisory role to numerous agencies on real-time public health surveillance including HHS, DHS, CDC, IOM, WHO and the White House. He was awarded the Presidential Early Career Award for Scientists and Engineers, the highest honor bestowed by the United States government to outstanding scientists and the Lagrange Prize for international achievements in complexity sciences. Dr. Brownstein is co-founder of digital health companies Epidemico and Circulation and an ABC Medical News Contributor. He has authored over 250 peer-reviewed articles on epidemiology and public health. This work has been reported on widely including pieces in the New England Journal of Medicine, Science, Nature, New York Times, The Wall Street Journal, CNN, National Public Radio and the BBC.
Drs. William F and Virginia Connolly Mitty Chair Director, Division of Medical Ethics, NYU Grossman School of Medicine, NY USA
Arthur Leonard Caplan PhD
Currently the Drs. William F and Virginia Connolly Mitty Professor and founding head of the Division of Medical Ethics at NYU School of Medicine in New York City.
Prior to coming to NYU School of Medicine, Dr. Caplan was the Sidney D. Caplan Professor of Bioethics at the University of Pennsylvania Perelman School of Medicine in Philadelphia, where he created the Center for Bioethics and the Department of Medical Ethics. Caplan has also taught at the University of Minnesota, where he founded the Center for Biomedical Ethics, the University of Pittsburgh, and Columbia University. He received his PhD from Columbia University.
Dr. Caplan is the author or editor of thirty-five books and over 800 papers in peer reviewed journals. His most recent books are Vaccination Ethics and Policy, (MIT Press, 2017 with Jason Schwartz) and, Getting to Good: Research Integrity in Biomedicine Springer, 2018 with Barbara Redman).
He has served on a number of national and international committees including as the chair of the National Cancer Institute Biobanking Ethics Working Group, chair of the Advisory Committee to the United Nations on Human Cloning; chair of the Advisory Committee to the Department of Health and Human Services on Blood Safety and Availability. He has also served on the Presidential Advisory Committee on Gulf War Illnesses, the special advisory committee to the International Olympic Committee on genetics and gene therapy, the Special Advisory Panel to the National Institutes of Mental Health on Human Experimentation on Vulnerable Subjects, the Wellcome Trust Advisory Panel on Research in Humanitarian Crises, and the co-director of the Joint Council of Europe/United Nations Study on Trafficking in Organs and Body Parts. He is the co-founder and a member of the ge2p2 global foundation.
Caplan has served since 2015 as the chairperson of the Compassionate Use Advisory Committee (CompAC), an independent group of internationally recognized medical experts, bioethicists and patient representatives which advises Johnson & Johnson’s Janssen Pharmaceuticals about requests for compassionate use of some of its investigational medicines.
Dr. Caplan is a regular commentator on bioethics and health care issues for WebMD/Medscape, WGBH radio in Boston, WOR radio in New York City and CNN. He appears frequently as a guest and commentator on various other national and international media outlets.
Dr. Caplan is the recipient of many awards and honors including the McGovern Medal of the American Medical Writers Association and the Franklin Award from the City of Philadelphia. He was a USA Today 2001 “Person of the Year and was described as one of the ten most influential people in science by Discover magazine in 2008. He has also been honored as one of the fifty most influential people in American health care by Modern Health Care magazine, one of the ten most influential people in America in biotechnology by the National Journal, one of the ten most influential people in the ethics of biotechnology by the editors of Nature Biotechnology, and one of the 100 most influential people in biotechnology by Scientific American magazine.
During the Covid-19 pandemic, he co-directs an advisory group on sports and recreation for the US Conference of Mayors, created a working group on coronavirus vaccine challenge studies, developed an ethical framework for distributing drugs and vaccines for J&J, helped develop rationing policies for NYU LMC and many other health systems, is a member of the WHO advisory committee on Covid, ethics and experimental drugs/vaccines, helped set policy for WIRB/WCG for research studies He was an advisor to Moderna. And serves on the NCAA Sports and Covid committee.
He received the Patricia Price Browne Prize in Biomedical Ethics for 2011. In 2014 he was selected to receive the Public Service Award from the National Science Foundation/National Science Board, which honors individuals and groups that have made substantial contributions to increasing public understanding of science and engineering in the United States. In 2016 the National Organization for Rare Disorders (NORD) honored him with their Rare Impact Award and hFood and Drug Law Institute’s Distinguished Service Leadership Award. In 2019 he was honored by the Food and Drug Administration’s, Reagan/Udall Foundation with its Innovation Award.
He holds seven honorary degrees from colleges and medical schools.
Managing Director at BioM Biotech Cluster Development GmbH, Planegg, Germany
Prof. Horst Domdey
In his scientific career, Horst Domdey worked at various German, Swiss and US institutes such as the Max Planck Institute of Biochemistry, the Swiss Institute of Cancer Research, the University of California at San Diego, the California Institute of Technology and the Munich Gene Center, where he was appointed as Professor of Biochemistry in 1994. In 1996 he successfully led the Munich Biotech Initiative into the German BioRegio Competition. Since 1997 he is the Managing Director of BioM, the development and management organization of the Munich Biotech Cluster, since 2006 he also directs the Bavarian Biotechnology Network. Among others he is a member of the boards of the Peter and Traudl Engelhorn Foundation and the Foundation for Stem Cell Research and Applied Regenerative Medicine.
Founding director of Julius Wolff Institute and Berlin Institute of Health Center for Regenerative Therapies (BCRT) Charité - Universitätsmedizin Berlin, Germany
Prof. Dr.-Ing. Georg N. Duda
Georg is the founding director of the Julius Wolff Institute at the Charité, Humboldt University and Free University of Berlin. The Julius Wolff Institute brings together researchers from engineering, mathematics, biology, biochemistry and clinical scientists in order to develop new therapeutic strategies for regeneration of injured or degenerated joint, bones and muscles. Conceptually, Georg’s research aims at understanding endogenous cascades of tissue formation, cytokine signaling and cellular self-organization especially in bone. This understanding is transferred to enable regeneration in clinically challenging healing scenarios of tissues normally capable of regeneration (bone) and those with intrinsic impaired regenerative capacity. Mechanical straining and adaptation due to mechanical cues plays a central role in all these tissues. The aim of Georg’s work is to understand the mechano-biological cues of regeneration and adaptation and how they can be employed to enable healing even in tissues with impaired regenerative capacity such as muscle, cartilage or tendon. All approaches are motivated by clinical challenges, employ basic research principles and aim at being translated into daily clinical routine. Examples of translation include innovative concepts for joint replacement procedures, angle stable fixation of implants or cell therapies for muscle regeneration.
Given his broad interest, core to all his activities is the close collaboration with clinical partners, specifically the scientific education of clinical scientists as core members of his team of research.
Georg Duda is Professor of Biomechanics and Musculoskeletal Regeneration at the Charité – Humboldt University of Berlin and Free University of Berlin and an Associated Faculty Member at the Wyss Institute for Biologically Inspired Engineering at Harvard University. He received his Master’s degree in precision engineering from the Technical University of Berlin, Germany, in 1991 and his Ph.D. degree in Mechanical Engineering from the Technical University of Hamburg-Harburg in 1996. He has been recipient of over a dozen awards for inventions, start-up engagements and PhD student mentoring.
Regius Professor of Medicine University of Glasgow, Scotland
Professor Dame Anna Dominiczak
Professor Dame Anna Dominiczak is Regius Professor of Medicine at the University of Glasgow; Honorary Consultant Physician and Endocrinologist at NHS Greater Glasgow and Clyde; and Health Innovation Champion for the Medical Research Council. In 2016, she was awarded a DBE for services to cardiovascular and medical science.
Professor Dominiczak is currently seconded to the Department of Health and Social Care in the UK Government as Director of Laboratories, NHS Test & Trace. In March 2020, she successfully led the establishment of the Lighthouse Laboratory in Glasgow (LLiG), leading to her current role where she continues to expand the Lighthouse laboratory network. She is accountable for the UK labs testing capability across a coordinated network of 13 labs. As the network continues to evolve, and very high throughput labs are brought online, Professor Dominiczak’s focus remains on delivering a triple helix partnership between academia, the NHS and industry to transform the long-term testing capability of the UK for COVID and beyond.
Recognised as a world-leading cardiovascular scientist and clinical academic, her major research interests are in hypertension, cardiovascular genomics and precision medicine, where she not only publishes extensively in top peer-reviewed journals (over 500 publications), but also excels in large scale research funding for programmes and infrastructure (with a total value in excess of £100M over the last eight years).
Managing Partner at German Accelerator Life Sciences, Cambridge, Massachusetts, USA
Marc Filerman is a healthtech entrepreneur and intrapreneur with expertise in market development, commercialization, and innovation acceleration. He has broad experience leading marketing, sales, and business development for large companies and startups. Marc co-founded a molecular imaging startup, was Chief Commercial Officer at an NIH-funded hometech venture, and was an Accelerator Executive with the CIMIT accelerator at Massachusetts General Hospital. Prior to his entrepreneurial endeavors Marc held corporate leadership positions in multiple large healthtech companies, including VP of Global Marketing at iCAD, Group Director of Marketing at Smith & Nephew, and Director of Global Marketing and Strategy at Hill-Rom. Marc holds BS and MS degrees from MIT in Mechanical Engineering, did his graduate work at the MIT AI Lab, and started his career as an engineer designing ultrasound imaging equipment for echocardiography.
Partner at Mass General Brigham Ventures, Cambridge, Massachusetts, USA
Dr. Meredith Fisher
Dr. Meredith Fisher is a Partner with the Innovation Fund focusing on early stage investments and company creation. Previously, she was in the private office at Bracebridge Capital serving as Director of Private Investments where she led investments in early stage life science companies. Prior to that role she led business development for Ginkgo BioWorks- an MIT spin out- and was Senior Director of Technology and Business Development at PureTech Ventures. She spent several years working as a scientist in drug discovery and assay development for Idenix Pharmaceuticals and Anadys Pharmaceuticals. Meredith serves as a board member on Nocion, ClarisBio, ZielBio and Mediar Therapeutics where she is co-founding CEO. She is an Observer on Amolyt Pharma and Scorpion Therapeutics. Meredith received her undergraduate degree from Mount Holyoke College, her MBA from the MIT Sloan School of Management and her PhD from Harvard University.
Heinz-Nixdorf-Chair of Biomedical Electronics, Director TranslaTUM at TU München, Germany
Prof. Dr. Oliver Hayden
Director of the Center for Translational Cancer Research (TranslaTUM), Campus University Hospital Klinikum rechts der Isar, TUM, Germany
Heinz-Nixdorf-Chair of Biomedical Electronics, Department of Electrical and Computer Engineering, TU Munich, Germany
11/2016 - 05/2017
Head of In-Vitro Diagnostics & Bioscience Germany, Siemens Healthcare GmbH, Technology Center, Erlangen, Germany
05/2015 - 10/2016
Senior Key Expert Scientist at Siemens Healthcare GmbH, Technology Center, Erlangen, Germany
05/2007 - 04/2015
Program Manager at Siemens AG, Corp. Technology, Erlangen, Germany
08/2005 - 04/2007
Visiting Scientist at IBM Research GmbH, Zürich Research Laboratory, Rüschlikon, Switzerland
01/2000 - 07/2005
Assistant Professor at the Institute of Analytical Chemistry, University of Vienna, Austria
2017 - European Inventor Award (category industry for hematology analysis of Plasmodium infections, Patent EP 2 635 695 B1, 2011)
2016 - Innovation Award of AMA (Association for Sensors & Measurement)
2013 - Siemens NTF Award for Medical Imaging IP portfolio 2006 EUREKA Lillehammer Award (E! 2497 Euroenviron BIOMAC) 2002 Young Investigator Award of the Austrian Chemical Society
2000/2001 - Award winner of “Best of Biotech” for start-up competition “Polymimetics”
Research Expertise & Interests
- Current research @ TUM: in vitro & in vivo diagnostics
- Industrial research: 12yrs in the semiconductor and healthcare industry on post-CMOS, medical imaging, in vitro diagnostics, and bioscience topics
- Academic training: 5yrs on piezoacoustic sensing and semiconducting nanowire sensing
Founder and Chief Science Officer at Sofregen Medical, Framingham, Massachusetts, USA
Dr. Anh Hoang
Dr. Anh Hoang, is the founder of Sofregen Medical, a medical device company that re-invents silk protein for tissue engineering. At Sofregen, Anh currently operates as the chief science officer and serves on the board of directors. Under her leadership, Sofregen obtained the first FDA clearance for the use of re-constituted silk protein for a medical application.
Outside of Sofregen, Anh is a faculty at Massachusetts Institute of Technology’s Catalyst LinQ program . She serves on the Medtech Advisory Group at the Massachusetts Biotechnology Council and on the Steering Committee of MassMedic Ignite Program. She was a recipient of the 2018 Medtech Boston 40 under 40 Healthcare Innovators.
Anh completed her doctorate degree (Ph.D) in material science engineering from Vanderbilt University and her postdoctoral fellowship at Harvard Medical School and Massachusetts General Hospital as an Executive Committee on Research fellow. Anh is a proud graduate of Mount Holyoke College where she earned her bachelor’s degree in biochemistry.
Managing Partner at Wellington Partners Life Sciences (WPLS), Munich, Germany
Dr. Regina Hodits
Regina is a Managing Partner at Wellington Partners Life Sciences (WPLS) and represents the WPLS funds on the Boards of Ayoxxa, Carisma Therapeutics, ONWARD, Sidekick, SNIPR Biome and STipe Therapeutics. She was a founding investor in Rigontec (acquired by MSD), Sapiens (acquired by Medtronic), Middle Peak Medical (acquired by Symetis / Boston Scientific), represented Wellington Partners of the Board of Themis (acquired by MSD), and served as the Spokesperson for the Board of the German PE and VC Association (BVK). Since joining the industry in 2000, she has become an influential investor in the European VC industry, focusing on early-stage and growth deals in Life Sciences.
Before joining WPLS, Regina led the European life sciences efforts of Boston-based Atlas Venture. She was the founding investor in Bicycle Therapeutics (NASDAQ: BCYC), F-star (NASDAQ,: FSTX) and Jenavalve, and served on the Boards of U3 Pharma (acquired by Daiichi Sankyo), Nitec Pharma (now part of Horizon Pharma NASDAQ HZPN), and Novamed (acquired by SciClone NASDAQ SCLN). Before, Regina worked for Apax Partners and McKinsey.
Regina studied chemical engineering in Vienna and holds a Ph.D. in biochemistry, and was as post-doctoral researcher at the MRC, Cambridge UK.
Senior Director Venture Investments Leaps by Bayer, Cambridge, MA, USA
Dr. Lucio Iannone, PhD
Lucio Iannone is an investor at Leaps by Bayer, the investment arm of the global life sciences company Bayer. Lucio is responsible for developing investment cases and deal execution. He is also involved in the sourcing, screening, and mentoring of companies with game-changing science. As an investor, Lucio is serving as board member for Pyxis Oncology, Khloris Biosciences, Vesigen Therapeutics , Immunitas Therapeutics, eGenesis, Azitra, Kojin Therapeutics and Axxam. Before joining Leaps by Bayer, he had several senior roles in biotechnology companies and venture capital firms. He has experience with molecular biology, cell & gene therapy technologies and their application in oncology and other therapeutic fields. Lucio obtained his Ph.D. in Medicine at the Imperial College of London and Master in Molecular Biology from Cambridge University.
Senior Vice President RNA Protein Replacement Therapies at BioNTech, Mainz, Germany
Prof. Dr. Katalin Karikó
Katalin Karikó is Senior Vice President at BioNTech RNA Pharmaceuticals from 2013. She is also Adjunct Associate Professor at the Perelman School of Medicine, University of Pennsylvania, where she worked for 24 years. She received her PhD in biochemistry from University of Szeged, Hungary, in 1982. For four decades, her research has been focusing on RNA-mediated mechanisms with the ultimate goal of developing in vitro-transcribed mRNA for protein therapy. She investigated RNA-mediated immune activation and co-discovered that nucleoside modifications suppress immunogenicity of RNA. This groundbreaking work unlocked the opportunity for the therapeutic use of mRNA. Her patents, co-invented on nucleoside-modified uridines of mRNA, was the foundation for the FDA-approved anti-SARS-CoV-2 mRNA vaccines developed by BioNTech/Pfizer and Moderna/NIAID that are crucial to ending the global pandemic.
CEO at Verve Therapeutics, Cambridge, USA
Sekar Kathiresan, M.D.
Sekar Kathiresan is co-founder and chief executive officer of Verve Therapeutics and serves on the company’s board of directors. He is a preventive cardiologist who has made groundbreaking discoveries of cardioprotective genetic mutations, which confer resistance to cardiovascular disease. Prior to joining Verve, he served as director of the Massachusetts General Hospital (MGH) Center for Genomic Medicine and was the Ofer and Shelly Nemirovsky MGH Research Scholar. He also served as director of the Cardiovascular Disease Initiative at the Broad Institute and was professor of medicine at Harvard Medical School. His research laboratory focused on understanding the inherited basis for blood lipids and myocardial infarction and using these insights to improve preventive cardiac care. Among his scientific contributions, he has helped highlight new biological mechanisms underlying heart attack, discovered mutations that protect against heart attack risk, and developed a genetic test for personalized heart attack prevention. He was honored with a Distinguished Scientist Award from the American Heart Association in 2017 and the 2018 Curt Stern Award from the American Society of Human Genetics. In tandem with his research, his clinical focus was the primary prevention of myocardial infarction in individuals with a family history of heart attack. He graduated summa cum laude with a B.A. in history from the University of Pennsylvania and received his M.D. from Harvard Medical School. He completed his clinical training in internal medicine and cardiology at MGH and his postdoctoral research training in human genetics at the Framingham Heart Study and the Broad Institute.
Chief Executive Officer at Charité – Universitätsmedizin Berlin, Germany
Prof. Dr. Heyo K. Kroemer
A pharmacologist by trade, Prof. Kroemer was born in 1960 in the Eastern Friesland area of Germany, Prof. Kroemer trained as a pharmacologist. From 2000 to 2012, he was Dean of the Medical School at the institution now known as the University of Greifswald. In 2011, he was appointed Scientific Director of Universitätsmedizin Greifswald. After joining the Board in 2007, Prof. Kroemer became President of the German Association of Medical Faculties (MFT) in 2012, a position he held until 2019. During this time, he was both Dean and Chairman of the Board of the University of Göttingen Medical Center. Prof. Kroemer was appointed Charité’s Chief Executive Officer on 1 September 2019.
Senior Consultant – Market Access & Regulatory Strategie at Kalms Consulting, Berlin
Dr. Madeleine Künz
Dr. Madeleine Künz academic background is reseach in Molecular Life Sciences, Structure Biology and Chemistry. Before joining Kalms Consulting, she worked for over 10 years in international research facilities and the pharmaceutical industry. Her research mainly concentrated on rational drug development in international interdisciplinary working groups combining approaches from structural biology, biophysics and chemistry. Her understanding of medical technologies is supported by her additional education and work experience as a paramedic for 7 years as well as advanced education in health technology assessment (HTA). Especially diagnostic but also therapeutic procedures including digital health products are part of her expertise. Furthermore, differentiation as well as compatibility assessments allow her to draw an accurate picture of innovation´s value. Her work in Kalms Consulting is centered around the assessment of innovative technologies and translation of these into options for the regulatory and market access strategy.
National Clinical Director at Scottish Government, Scottland
Professor Jason Leitch, CBE
National Clinical Director
Jason has worked for the Scottish Government since 2007 and in January 2015 was appointed as The National Clinical Director in the Health and Social Care Directorate. He is a Scottish Government Director and a member of the Health and Social Care Management Board. He is one of the senior team responsible for the NHS in Scotland.
He is an Honorary Professor at the University of Dundee.
Jason was the 2011 UK Clinician of the Year.
He is a Senior Fellow at the Institute for Healthcare Improvement (IHI). He was a 2005-06 Quality Improvement Fellow at IHI, in Boston, sponsored by the Health Foundation.
CTO at Sight Diagnostics, Israel
Sarah joined Sight to build and lead its technology dream-team. She is responsible for all of Sight's R&D as well as its medical-regulation activities. Top of her class at the elite Talpiot program, Sarah gained her technology leadership experience during a brilliant military career, where she commanded elite cyber security and intelligence special technology units.
Sarah holds as M.Sc. in Condensed Matter Physics from the Weizmann Instituter of Science, and a B.Sc in Physics & Mathematics (magna cum laude) from the Hebrew University of Jerusalem.
Managing partner and founder WAVE STRATEGY, Cleveland, Ohio, USA
Neema Mayhugh, PhD
Neema Mayhugh is a healthcare innovation expert who helps large academic medical centers and biotechnology incubators bridge the gap between research and product delivery. Neema designs and executes a comprehensive strategy to take technology from bench to bedside -- engaging partners, securing capital, and delivering desired outcomes, always with an eye toward ensuring the highest quality patient care and enhancing the patient experience.
Built on a solid foundation of clinical innovation, Neema’s expertise stems from strong basic research training and early positions in healthcare management consulting and with Pfizer, Inc. Her specialization then grew rapidly when she joined the industry-leading Cleveland Clinic, where her roles and responsibilities expanded to include:
~ Start-up formation
~ Intellectual property portfolio prioritization
~ Clinical trial management and execution
~ Sponsored research program negotiation
~ Management of commercialization projects
~ Strategic portfolio oversight
As Chief Operating Officer of Mobile Hyperbaric Centers, Neema expanded her expertise base again, overseeing operations for seven hospital centers and all corporate functions including insurance authorization, billing, documentation, compliance, human resources and center safety and maintenance.
Neema holds a Doctoral degree in Pharmacology & Toxicology from Dartmouth College and a Bachelors of Science in Human Physiology from Boston University.
Chair of Cardiology & Consultant Cardiologist at University of Edinburgh
Current post: British Heart Foundation (BHF) Butler Senior Clinical Research Fellow (personal fellowship, 2016-2021) and Personal Chair of Cardiology, BHF/University Centre for Cardiovascular Science, University of Edinburgh. Consultant Interventional Cardiologist, Royal Infirmary of Edinburgh.
2013 - 2015 Reader in Cardiology, University of Edinburgh
2011 - 2016 BHF Intermediate Clinical Research Fellow, University of Edinburgh
2011 - 2013 Senior Lecturer in Cardiology, University of Edinburgh
2007 - 2011 Clinical Lecturer in Cardiology, University of Edinburgh
2005 - 2011 Specialist Registrar in Cardiology, Royal Infirmary of Edinburgh
2005 - 2007 Michael Davies/British Cardiac Society Research Fellow, University of Edinburgh
2003 - 2005 British Heart Foundation Research Fellow, Edinburgh University, Edinburgh
2001 - 2003 South East of Scotland Senior House Officer Rotational Training Scheme in Medicine
2000 - 2001 Pre-registration House Officer Posts, Western General Hospital, Edinburgh
BSc (First Class Honours) Edinburgh University 1998
MB ChB Edinburgh University 2000
MRCP Royal College of Physicians 2003
PhD Edinburgh University 2009
British Heart Foundation UK Cardiovascular Regeneration Medicine centre Award Renewal (RM/17/3/33381). 2017 for 4 year (£2.5 million). (Principal Investigator, Prof Andrew Baker).
Duration of dual anti-platelet therapy in acute coronary syndrome across Scotland. The DUAL-ACS2 Trial. BHF Clinical Study Grant (CS/17/4/32960). 2017 for 5 year (£630k). (Principal Investigator, Prof David Newby).
Refining the diagnosis of type 2 myocardial infarction. BHF Clinical Research Training Fellowship (FS/16/75/32533). 2016 for 3 years (£283k) for Dr Andrew Chapman.
High-sensitive cardiac troponin and coronary heart disease. BHF Butler Senior Clinical Research Fellowship (FS/16/14/32023). 2016 for 5 years (£1.2m).
Identification and characterisation of a vessel wall endothelial progenitor cell, and its potential for vascular regeneration. BHF Intermediate Research Fellowship (FS/16/4/31831). 2016 for 4 years (£540k).
High-sensitivity cardiac troponin on presentation to rule out myocardial infarction (HiSTORIC): A randomised controlled trial. BHF Project Grant (PG/15/51/31596). 2015 for 3 years (£272k)
BHF UK Cardiovascular Regenerative Medicine Centre Award (RM/13/2/30158). 2013 for 4 years (£2.5m).
Lipid mediators as predictors of nanoparticle-induced cardiovascular disease. BHF Special Project Grant (SP/15/8/31575). 2015 for 4 years (£538k).
Development of a clinical translational model of arterial injury and repair to assess vascular stem cell therapies. BHF Project Grant. 2013 for 3 years (£299k).
High-sensitive troponin in the evaluation of patients with acute coronary syndrome (HighSTEACS): A randomised controlled trial. BHF Special Project Grant (SP/12/10/29922). 2012 for 3 years (£702k)
Professor and Director Center for Bioengineering at The Hebrew University of Jerualem, Israel
Prof. Yaakov Nahmias
Prof. Yaakov “Koby” Nahmias is a bioengineer and innovator, whose breakthroughs ranged from the first 3D printing of cells to the first commercial human-on-chip technology. He is a Magna Cum Laude graduate of the Technion, Israel Institute of Technology, and is the founding director of the Grass Center for Bioengineering of the Hebrew University of Jerusalem. Nahmias is a recipient of a NIH career award, two European Research Council (ERC) grants, the Kaye Innovation Award and the prestigious Rappaport Prize in Biomedical Research. He is the first scientist outside Britain to win the Rosetrees Trust Prize. Nahmias is the co-founding director of BioDesign-Israel an entrepreneurship program that educated over 120 fellows, and launching 6 startup companies including Guide In Medical, CardioVia and Swiftduct. Nahmias is the founder and CSO of two biotechnology startups, including Tissue Dynamics that is developing a groundbreaking human-on-chip instruments for drug development, and the Tyson Foods-funded Future Meat Technologies focusing on the cost-effective production of cultured meat.
Professor Emeritus Physiology and Biophysics Technion University, Israel; Founder and Chief Technology Officer Novocure, Israel
Professor Yoram Palti, MD Ph.D.
Professor Yoram Palti received his M.Sc., Ph.D. and M.D. from The Hebrew University Hadassah Medical School, Jerusalem. He was appointed an Associate Professor of Physiology at the University of Maryland School of Medicine in 1969 and an Assoc Prof. of Physiology and Biophysics at the Technion Medical School in 1971 and Full Prof. in 1976. Currently he is Prof. Emeritus at the Technion.
Palti served as the Head of the Dept. of Physiology & Biophysics (1971- 1991) and as the Head of the Rappaport Family Institute for Research in the Medical Sciences, the research arm of the Technion, from its establishment in 1982 till 1993.
Professor Palti has founded several startup companies, for example: Carmel Biosensors, Echosense, O2Cure, BG Guard and the highly successful Novocure that was established in 2000 and currently has a Cap value of over $20 Billion (NVCR). At NovoCure Palti served as Director through 2018 and serves as the company’s Chief Technology Officer to date.
Founder of Emerging Health Ventures, Stockholm, Sweden
Dr. Nina Rawal
Dr. Nina Rawal is the founder of Emerging Health Ventures. Previously, she headed the life science investment team at Industrifonden, a 600 million EUR venture capital fund. Previous experience also includes of Vice President, Strategy and Ventures at Gambro AB, and management consulting at Boston Consulting Group in Stockholm and New York. She serves on the boards of MedCap AB (publ) and Stockholms Sjukhem, a non-profit hospital and health care organization. She holds a PhD in Molecular Neurobiology, and a MSc in Biomedicine, both from the Karolinska Institute, including research work done at Columbia University in New York and at Hôpital la Salpêtrière in Paris.
Recognition for her work includes the selection as a Young Global Leader by the World Economic Forum and a '40 under 40 - European Young Leader' by Friends of Europe/Europanova.
Partner at aMoon, Ra'anana, Israel
Gur Roshwalb, MD
Dr. Gur Roshwalb is a Partner at aMoon, where he leads sourcing efforts, leads deals, manages the due diligence process, and sits on the board of AltruBio and Viracta Therapeutics, aMoon Growth portfolio companies. Beginning his career as a practicing physician, Gur understands the urgency driving the innovation in the healthcare industry. He moved to Israel in 2019 to work with aMoon to accelerate HealthTech advances into clinical practice. Gur has over 20 years of healthcare industry and finance experience. Prior to joining aMoon, he was CEO at several private and public biotech companies. Earlier, Gur was a Vice President at Venrock, where he was an investment professional on the healthcare team investing in both private and public companies. Gur started his finance career at Piper Jaffray, where he worked as a vice president and equity analyst, publishing research on specialty pharmaceutical companies. Prior to Piper, Gur was in private practice in New York following residency training in internal medicine at Mount Sinai Medical Center, where he also served as Chief Resident. Gur obtained his medical degree from Albert Einstein College of Medicine of Yeshiva University, his MBA from the NYU Stern School of Business, and a B.A. from Columbia University.
Investment Analyst at HTGF, High-Tech Gründerfonds, Bonn, Germany
Niels Sharman is an Investement Analyst within the Life Sciences team of HTGF. He holds a bachelor degree in biology from the Ludwig-Maximilians-University Munich and a master in management from the Technical University Munich. In the past he gained experience in the pharmaceutical industry and contributed to a biotech start-up.
President at The Hastings Center, Garrison, New York USA
Mildred Z. Solomon
Mildred Z. Solomon, EdD is the President of The Hastings Center, the nation’s founding bioethics research institute, focused on examining the social and ethical implications of health and health care, science, and emerging biomedical technologies. She is also Professor (part-time) of Global Health and Social Medicine at Harvard Medical School, where she runs a Fellowship in Bioethics and has trained over 200 scientists, physicians and other kinds of professionals from across the United States and around the world. Dr. Solomon’s own research covers a broad spectrum of topics -- including, for example, the ethics of end-of-life care, organ transplantation, medical professionalism, and responsible conduct of research. She recently completed a two-year term on the World Economic Forum’s Global Futures Council on Technology, Values and Policy. She has served on committees of the National Academies of Sciences, Engineering and Medicine, on the US Secretary of Health and Human Services’ Advisory Committee on Organ Transplantation, and is currently a member of the Global Health Advisory Committee of the Open Society Foundations’ Public Health and Human Rights Programs. Dr. Solomon has over 70 academic publications in peer-reviewed journals and is also frequently cited in the mainstream media, including the Wall Street Journal, National Public Radio, New York Review of Books, The Daily Beast, Forbes, Science News, The Scientist and other outlets. A frequent public speaker, she has presented at Aspen Health, the New York Academy of Sciences, academic medical centers, and numerous public venues. Before leading The Hastings Center, she was Senior Director for Implementation Science at the Association of American Medical Colleges and before that, Vice President of Education Development Center, an independent research institute in Boston, MA. Dr. Solomon holds a B.A from Smith College and a doctorate in educational research methods from Harvard University.
Project Manager Digital Health and Scouting at BIH Digital Labs, Berlin, Germany
2007 Diploma Product Design, Bauhaus University Weimar
2010 MA Medical Design, Muthesius School of Arts, Kiel
2011-2015 Brand Strategist, f+d design studios, Hamburg
2015 Consultant, diffferent strategy consultancy, Berlin
2015-2017, Design Lead Participatory Health Unit , IXDS, Berlin
2017-2020, Service Design Lead, designit Germany, Berlin
since Dec 2020, Project Manager Digital Health and Scouting, Berlin Institute of Health, Berlin
CEO at Wellinks, New Haven, Connecticut, USA
Alex Waldron is Chief Executive Officer at Wellinks, a COPD-focused digital health company fueled by a mission to empower people in their pursuit to breathe freely. Wellinks’ lead asset is a digitally enabled and outcomes-driven holistic virtual care management solution for COPD, with a focus on reinventing respiratory care. The company’s expertise in COPD innovation began with the development and FDA 510(k) clearance of Flyp Nebulizer, the first truly pocket-portable nebulizer, allowing patients simple, convenient, and connected access to breathing treatments. Wellinks connects individuals and their caregivers through a suite of medical devices and intuitive software, enabling virtual COPD care management based on information that is real-time, accurate, and actionable.
Executive global bio/pharmaceutical business leader with 25+ years of experience with large pharmaceutical, fully integrated biopharmaceutical and startup organizations.
Founder & CEO at Investing Women Angels & AccelerateHER, Edinburgh, Founder & CEO at Investing Women Angels & AccelerateHER, Edinburgh, Scotland
Jackie Waring MA (Hons), DMS, DipM, MSc Founder & CEO, Investing Women Angels & AccelerateHER
Jackie is a pioneer of women angels ‘changing the face of angel investing’; bringing more women angels into Scotland’s dynamic angel investment community. An active and experienced angel investor herself; she established and leads Scotland’s all-female angel group Investing Women Angels whose members have invested over 80% of their funds in highly innovative female founded/co-founded companies.
Jackie is an entrepreneur with a passion for helping other entrepreneurs. It was this passion which inspired her to establish AccelerateHER; creating a channel and direct help for female founders going for scale. Publicly recognised by Scotland’s First Minister; she is a major player in shaping the ScotCanDo eco-system. The AccelerateHER Awards, workshops, mentoring and other support are achieving tangible impact; boosting the volume and investment in Scotland’s female-led companies. She has also nurtured strong international partnerships leading to regular AccelerateHER missions to Silicon Valley, Dubai, Berlin; and now Boston and New York in partnership with Founders Forum:
Jackie has previously run three companies, including 10 years CEO of a business/economic development organisation in Scotland. She has also been an external policy advisor to UK government; leading on the access to finance agenda for women entrepreneurs.
Professor at Whitehead Institute/MIT, Cambridge, Massachusetts, USA
Professor Richard Young
Richard Young is a Professor at the Whitehead Institute and MIT. Dr. Young studies gene regulation in health and disease and has mentored more than 100 graduate and postdoctoral students, many of whom now lead academic and commercial research programs and enterprises. Young has served as an advisor to the World Health Organization, the National Institutes of Health and numerous scientific societies and journals. His honors include Membership in the National Academy of Sciences and the National Academy of Medicine, and Scientific American has recognized him as one of the top 50 leaders in science, technology and business. He has founded and advised companies in the biotechnology and pharmaceutical industry, and currently serves on the boards of Syros Pharmaceuticals, CAMP4 Therapeutics, Omega Therapeutics and Dewpoint Therapeutics. Young is also an aviator and holds a commercial pilot license.